<DOC>
	<DOCNO>NCT02525380</DOCNO>
	<brief_summary>Safety efficacy doxorubicin-eluting-bead embolization patient advance hepatocellular carcinoma .</brief_summary>
	<brief_title>Safety Efficacy Doxorubicin-eluting-bead Embolization Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Transarterial chemoembolization ( TACE ) represent first-line non-curative therapy hepatocellular carcinoma ( HCC ) . TACE associate unsatisfactory long-term outcome . The objective response rate TACE 15 % 55 % , tumor recurrence rate 70 % 5 year . One potential reason may increase plasma vascular endothelial growth factor ( VEGF ) level TACE . Disturbances tumor microenvironment follow TACE result increase hypoxia , lead up-regulation hypoxia inducible factor-1a , turn up-regulates VEGF platelet-derived growth factor receptor ( PDGFR ) increase tumor angiogenesis . TACE consider patient unresectable HCCs also ineligible local ablative therapy . The lack portal blood flow ( portal vein thrombosis , portosystemic anastomosis hepatofugal flow ) consider main contraindication TACE . However , report TACE safely perform select population patient main portal vein invasion , well-preserved liver function due collateral blood supply . DC Beads novel drug delivery embolization system comprise biocompatible , non-resorbable polyvinyl alcohol polymer hydrogel bead load cytotoxic drug . The bead high affinity drug enable gradual release doxorubicin tumor , allow longer intratumoral exposure less systemic exposure drug , reduce systemic toxicity . One multivariate analysis study show median survival duration patient portal vein invasion treat DC-bead TACE ( DEBDOX ) 176 day , retrospectively . In international , multicenter , randomize phase II trial , drug-eluting bead group show high rate complete response objective response compare cTACE group ( 27 % vs. 22 % , 52 % vs. 44 % respectively ) . The hypothesis superiority meet . However , patient Child-Pugh B , ECOG 1 , bilobar disease , recurrent disease show significant increase objective response compare cTACE . Here , investigator investigate safety efficacy DC Bead TACE patient advance HCC portal vein invasion .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>[ Stage C HCC accord BarcelonaClinic Liver Cancer ] 1 . Clinical histological diagnosis HCC base guideline American Association Study Liver Diseases . 2 . At least one typical enhance lesion bidimensionally measurable multiphasic spiral CT scan dynamic contrastenhanced MRI . 3 . Tumor condition confirm abdominal imaging ( contrast enhance CT ± MRI ) perform within 1 month prior enrollment : 4 . ECOG Performance Status 0 1 . 5 . ChildPugh class A B ( ChildPugh score ≤ 7 ) . 6 . Life expectancy least 16 week . 7 . Adequate bone marrow , liver , renal function assess follow laboratory requirement ( transfusion , restoration ) , conduct within 14 day prior screen : Hemoglobin ≥ 8.0 g/dL Absolute neutrophil count ≥ 1,000/mm3 Platelet count ≥ 50,000/μL Total bilirubin &lt; 2.5 mg/dL Serum albumin ≥2.8 g/dL ALT AST &lt; 5 × upper limit normal PTINR ≤ 2.3 Prothrombin Timesec ≤ 6 sec Serum creatinine ≤ 1.7 mg/dL 1 . A history receive systemic therapy molecularly target agent , immunotherapy cytotoxic chemotherapy treatment HCC 2 . Invasion inferior vena cava ( Vv3 ) , invasion first order branch biliary duct ( B3 ) 3 . History presence hepatic encephalopathy 4 . Ascites , moderate , large intractable 5 . Active clinically serious infection ( &gt; grade 2 , NCICTC version 4.0 ) , include spontaneous bacterial peritonitis . 6 . Untreated active chronic hepatitis B 7 . Esophageal gastric varices≥ F2 ( grade 2 ) red color sign positive without prophylaxis 8 . Active ulcer stomach duodenum : untreated presence visible vessel 9 . Any major surgery within 4 week , minor surgery within 2 week prior sign inform consent form 10 . Candidate liver transplant history liver transplantation 11 . History cardiac disease : congestive heart failure great NYHA class 2 ; active coronary artery disease ; cardiac arrhythmia require antiarrhythmic therapy uncontrolled hypertension diabetes mellitus 12 . History AIDS/HIV infection . 13 . Seizure disorder require medication . 14 . History organ allograft . 15 . Evidence history bleed diathesis , thromboembolic event require treatment 16 . Current renal dialysis . 17 . Previous concurrent cancer primary site histology distinct HCC , except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis , T1 ] cancer curatively treat less 3 year prior enrollment . 18 . History alcohol abuse ( male &gt; 210g/week , female &gt; 140g/week ) 19 . Any contraindication chemoembolization except major branch portal vein invasion 20 . Any contraindication doxorubicin administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Transarterial chemoembolization</keyword>
	<keyword>Doxorubicin-Eluting-Bead Embolization</keyword>
	<keyword>DC Bead TACE</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
</DOC>